



Trogarzo® Phase III Data Analysis featured During Late-Breaking Oral Presentation at HIV Drug Therapy Glasgow 2018

October 31, 2018

Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced that additional analysis of phase III clinical trial data of Trogarzo® (ibalizumab-uiyk) injection was presented today during a late-breaking clinical trial session at HIV Drug Therapy Glasgow 2018.